2021 LGBTQ+ Forum

Dr. Arturo Molina is a hematologist/oncologist and Chief Medical Officer at Sutro Biopharma in South San Francisco where he is responsible for the clinical development of oncology therapeutics. He is a volunteer attending medical staff physician in oncology at the Veterans Affairs Palo Alto Health Care System, adjunct clinical faculty in the department of medicine (oncology) at Stanford University School of Medicine and immediate Past President of the Stanford Medicine Alumni Association. Since 2006, Dr. Molina has been on the National Advisory Committee of the Amos Medical Faculty Development Program, a Robert Wood Johnson Foundation Program focused on increasing the number of medical, dental, and nursing faculty from historically disadvantaged backgrounds. Dr. Molina is also a member of American Society of Hematology (ASH)'s Committee on Promoting Diversity.

  
Dr. Molina was previously Vice President, Oncology Scientific Innovation at Johnson & Johnson (JNJ) Innovation where he was involved in the evaluation of novel biologics and small molecules with a focus on immuno-oncology. At JNJ, he was also Vice President Clinical Research, Oncology, where he was responsible for the clinical development and global registration-directed studies of ZYTIGA® (abiraterone acetate) in a multitude of countries for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Previously, Dr. Molina served as Chief Medical Officer and Executive Vice President of Cougar Biotechnology where his leadership efforts advanced the company's abiraterone program, Zytiga®, from phase I into several global phase III studies prior to being acquired by JNJ. Before joining Cougar Biotechnology, Dr. Molina worked at IDEC as Senior Director, Medical Affairs, ultimately becoming Department Head, Oncology Clinical Development for Biogen-IDEC. In collaboration with Genentech, he led clinical Supplemental Biologics License Application filing activities resulting in the FDA approval of Rituxan® (rituximab) in front-line follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

  
Dr. Molina was a faculty staff physician in Hematology/Bone Marrow Transplantation and Medical Oncology/Therapeutics Research at the City of Hope (COH) Comprehensive Cancer Center, where he became an Adjunct Professor, member of the COH Medical Group Board of Directors and President-Elect of the City of Hope Medical Staff. Dr. Molina received his M.D. and master's in Physiology from Stanford University School of Medicine. While at Stanford med school, he was a Teaching Fellow in the Chicano Fellows Program, School of Humanities and Sciences. Dr. Molina continued at Stanford for Residency in Internal Medicine and Fellowships in Medical Oncology, Biological Science, and Bone Marrow Transplantation. He is board certified in internal medicine and medical oncology. Dr. Molina was an undergraduate at the University of Texas (UT) at Austin where he received a B.S. in Zoology (Honors) and B.A. in Psychology (High Honors). At UT Austin, Dr. Molina was President, National Chicano Health Organization (local chapter).